Manuscript Number : IJSRST1254121

Role of Post Approval Clinical Trials for Drug

Authors(3) :-Jenil Nareshkumar Darji, Mrs.Krishna Kalsar, Dr. U M Upadhyay

Anti-tuberculosis drugs, the main aim for improving current treatment should be to optimize the use of the two current drugs, rifampicin and the pro-drug pyrazinamide, which are responsible to a similar extent for the entire sterilizing activity of current therapy. The rifamycin activity could be improved by increasing the dose size of rifampicin or by daily dosing with long acting rifapentine. Increasing the dose size of pyrazinamide is limited by toxicity but an alternative approach is to use inhalation with pyrazinoic acid, as an adjunct to standard oral therapy. This would acidify pulmonary lesions, thus increasing the bactericidal activity of the orally administered pyrazinamide. Because pyrazinoic acid is the active moiety, it should also increase overall pyrazinamide activity and, because most resistance arises in the pncA gene that converts pyrazinamide to pyrazinoic acid, it should act on most pyrazinamide resistant strains. Inhalation technology allows delivery of drug to lesions rapidly and without first pass toxicity. The properties of drug containing microparticles and nanoparticles during inhalation and storage are reviewed. Spray-dried larger Trojan particles in which the smaller encapsulated particles can reside should be able to improve localisation within alveoli and avoid some storage problems.

Authors and Affiliations

Jenil Nareshkumar Darji
Sharda University, Greater Noida, Uttar Pradesh, India
Mrs.Krishna Kalsar
Sharda University, Greater Noida, Uttar Pradesh, India
Dr. U M Upadhyay
Sharda University, Greater Noida, Uttar Pradesh, India

Rifampicin, Prednisolone, Rifampicin Resistance, M. Tuberculosis

  1. Acocella, G., and Billing, B. H. (1965). The effect of rifamycin SV on bile pigment excretion in rats. Gastroenterology, 49, 526-530.
  2. Acocella, G., Mattiussi, R., Nicolas, F. B., Pal Lanza, R., and Tesconi, L. T. (1968). Biliary excretion of antibiotics in man. Gut, 9, 536-545.
  3. Acocella, G., Nicolis, F. B., and Tenconi, L. T. (1965). The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein and indocyanine green in man.
  4. Gastroenterology, 49, 521-525. Berthelot, P. (1967). Excretion of unconjugated bilirubin in rat bile.
  5. In Bilirubin Metabolism, edited by I. A. D. Bouchier, and B. H. Billing, pp. 189-197. Blackwell, Oxford.
  6. Berthelot, P., and Billing, B. H. (1966). Effect of bunamiodyl on hepatic uptake of sulfobromophthalein in the rat. Amer. J. Physiol., 211, 395-399.
  7. Ohnhaus EE, Park BK. Measurement of urinary 6-3 hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme inducing capacity of antipyrine, phenobarbitone and rifampicin. EurJ Clin Pharmacol 1979; 15:139-45.
  8. Toverud EL, Boobis AR, Brodie MS, et al. Differential induction of antipyrine metabolism by rifampicin. EurJ Clin Pharmacol 1981 ;21 :155-60.
  9. Schoene B, Fleischman RA, Remmer H, Von Oldershausen HF. Determination of drug metabolising enzymes in needle biopsies of human liver. Eur J Clin Pharmacol 1973; 4:65 73.
  10. Jezequel AM, Orlandi F, Tenconi LT. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea pig hepatocytes. Gut 1971; 12:984-7.
  11. Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi T, Nicolis FG. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972 ;13 :47-53.
  12. Nocke-Finck L, Breuer H, Reimers D. Effects of antibiotics on oestrogen excretion in women taking oral contraceptives. Acta Endocrinol 1973;suppl 177:136.
  13. Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbitone and tolbutamide clearance. Eur 7 Clin Pharmacol 1975;9:219-27.
  14. O'Reilly RA. Interaction of sodium, warfarin and rifampicin studies in man. Ann Intern Med 1974;81 :337-40.
  15. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. Br MedJ7 1979; i:306.
  16. Buffington GA, Dominguez JH, Piering WF, Herbert LA, Kaufman HM, Leman J. Interaction of rifampicinand glucocorticoids. JAMA 1976;236: 1958-60.
  17. "Morrison PJ, Bradbrook ID, Rogers HJ. Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique. Br J Clin Pharmacol 1977; 4:597-603.
  18. Al-Habet SMH, McAllister WAC, Collins JV, Rogers HJ. Comparison of radioimmunoassay and thin layer chromatography assay methods for
  19. estimation of plasma prednisolone concentrations. J Pharmacol Methods 1981; 6:137-42.
  20. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1975.
  21. Tanner A, Bochner F, Caffin J, Halliday J, Powell L. Dose dependent prednisolone kinetics. Clin Pharmacol Ther 1979;25 :571-8.
  22. Al-Habet S, Rogers HJ. Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol 1980;1O:503-8.
  23. Gambertoglio JG, Amend WJC, Benet LZ. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm 1980; 5:257-70.
  24. Edwards OM, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. Lancet 1974; ii :549-51.
  25. Acta crystallogr. Korzheva, N., Mustaev, A., Nudler, E., Nikiforov, V., and Goldfarb,A47, 110-119.
  26. Mechanistic model of the elongation complex of Escherichia coli RNA polymerase. Cold Spring Harb. Symp. Quant. Biol. 63, 337-345.
  27. Korzheva, N., Mustaev, A., Kozlov, M., Malhotra, A., Nikiforov, V., Goldfarb, A., and Darst, S.A. (2000). A structural model of transcrip tion elongation. Science 289, 619-625.
  28. Lancini, G., and Zanichelli, W. (1977). Structure-activity relationships in rifamycins. In Structure-Activity Relationship in Semisynthetic An tibiotics, D. Perlaman, ed. (New York: Academic Press), pp. 531-600.
  29. Landick, R., Stewart, J., and Lee, D.N. (1990). Amino acid changes in conserved regions of the beta-subunit of Escherichia coli RNA polymerase alter transcription pausing and termination. Genes Dev. Lisitsyn, N.A., Gur'ev, S.O., Sverdlov, E.D., Moiseeva, E.P., and Niki 4,1623-1636.
  30. forov, V.G. (1984a). Nucleotide substitutions in the rpoB gene leading to rifampicin resistance of E. coli RNA polymerase. Bioorg Khim 10,127-128.
  31. Lisitsyn, N.A., Sverdlov, E.D., Moiseyeva, E.P., Danilevskaya, O.N., and Nikiforov, V. (1984b).
  32. Mutation to rifampicin resistance at the beginning of the RNA polymerase beta subunit gene in Escherichia coli. Mol. Gen. Genet. 196, 173-174.
  33. McClure, W.R., and Cech, C.L (1978). On the mechanism of rifampicin inhibition of RNA synthesis. J. Biol. Chem. 253, 8949-8956.
  34. Minakhin, L., Bhagat, S., Brunning, A., Campbell, E.A., Darst, S.A., Ebright, R.H., and Severinov, K. (2001a). Bacterial RNA polymerase subunit and eukaryotic RNA polymerase subunit RPB6 are sequence, structural, and functional homologs and promote RNA polymerase assembly. Proc. Natl. Acad. Sci. USA, 98, 892-897.
  35. Minakhin, L., Nechaev, S., Campbell, E.A., and Severinov, K. (2001b). Recombinant Thermus aquaticus RNA polymerase-A new tool for structure-based analysis of transcription, J. Bacteriol. 183, 71-76.
  36. Mooney, R.A., and Landick, R. (1999). RNA polymerase unveiled. Cell 98, 687-690.
  37. Morse, R., O'Hanlon, K., Virji, M., and Collins, M.D. (1999). Isolation of rifampin-resistant mutants of Listeria monocytogenes and their characterization by rpoB gene sequencing, temperature sensitivity for growth, and interaction with an epithelial cell line. J. Clin. Micro biol. 37, 2913-2929.
  38. Topology of the RNA poly merase active center probed by chimeric rifampicin-nucleotide compounds. Proc. Natl. Acad. Sci. USA 91,12036-12040.
  39. Mustaev, A., Kozlov, M., Markovtsov, V., Zaychikov, E., Denissova, L, and Goldfarb, A. (1997). Modular organization of the catalytic center of RNA polymerase. Proc. Natl. Acad. Sci. USA 94, 6641 6645.
  40. Nolte, O. (1997). Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new muta tions and notes on population genetics. J. Antimicrob. Chemother. 39, 747-755.

Publication Details

Published in : Volume 9 | Issue 6 | November-December 2022
Date of Publication : 2022-12-30
License:  This work is licensed under a Creative Commons Attribution 4.0 International License.
Page(s) : 126-140
Manuscript Number : IJSRST1254121
Publisher : Technoscience Academy

Print ISSN : 2395-6011, Online ISSN : 2395-602X

Cite This Article :

Jenil Nareshkumar Darji, Mrs.Krishna Kalsar, Dr. U M Upadhyay, " Role of Post Approval Clinical Trials for Drug", International Journal of Scientific Research in Science and Technology(IJSRST), Print ISSN : 2395-6011, Online ISSN : 2395-602X, Volume 9, Issue 6, pp.126-140, November-December-2022. Available at doi : https://doi.org/10.32628/IJSRST1254121    
Journal URL : https://ijsrst.com/IJSRST1254121
Citation Detection and Elimination     |      | | BibTeX | RIS | CSV

Article Preview